

Supplemental document to:

Identification and analysis of a novel NR0B1 mutation in late-onset adrenal hypoplasia congenita and hypogonadism


Yutaka Hasegawa, Yoshihiko Takahashi, Yuichiro Kezuka, Wataru Obara, Yoichiro Kato, Shukuko Tamura, Ken Onodera, Toshie Segawa, Tomoyasu Oda, Marino Sato, Koji Nata, Takamasa Nonaka and Yasushi Ishigaki

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Iwate Medical University, Yahaba, Japan

Mutation Taster (<http://www.mutationtaster.org/>)

Nucleotide Change	Amino Acid Change	Mutation Taster
c.884 T>A	p.Leu295His	Disease causing



Supplementary Figure. 1



Supplementary Figure. 2


HEK293 Cells

Wild-type NR0B1
 Mutat NR0B1
 p.Leu295His



STAR-Luc + + + +
 NR5A1 - + + +
 Wild-type NR0B1 - - + -
 Mutant NR0B1 (p.Leu295His) - - - +

Supplementary Figure. 3



Supplementary Figure. 4

Supplementary Figure Legends

Supplementary Figure 1. In silico analysis of the novel *NR0B1/DAX1* missense mutation

The p.Leu295His mutation in the *NR0B1/DAX1* gene was predicted “Disease causing” by Mutation Taster.

Supplementary Figure 2. Scheme of experimental procedures

Supplementary Figure 3. The functional analysis of mutant p.Leu295His *NR0B1/DAX1*

Immunoblotting of HEK293 cells with indicated transfections. α -Tubulin was used as loading control (left). Luciferase assay for NR5A1/SF1-mediated STAR transcriptional activity. STAR-luc, NR5A1/SF1 and *NR0B1/DAX1* (wild type and mutant p.Leu295His) expression vectors were co-transfected into HEK293 cells, n=4 (right). ** P<0.01, *** P<0.001.

Supplementary Figure 4. The scheme of NR5A1/EGR1-mediated synergistic activation of LH β

The gene expression of LH β was measured in H295R cells with indicated transfections.

Supplementary Table 1. Primer sequences used in the study.

Primer sequences used for quantitative RT-PCR.

Gene	Forward	Reverse
<i>AKR1B1</i>	GTGACACCAGCAGCATTG	GCATTGAAGGGATAGTCTTCCAA
<i>CYP11A1</i>	GAGGCCACGATTTCATTGAT	TCCTGAACAGACGGAACAGGT
<i>CYP11B1</i>	TCATGTTCAAATCCACCGTCC	GCTGGTGTACTGTTGAGGGC
<i>CYP11B2</i>	TTCAACCGCCCTCAACACTAC	GGAAACGCTGTCGTGTCCA
<i>CYP17A1</i>	CCGTAAGGGTATCGCCTTCG	CCATCCTTGAACAGGGCAAAG
<i>CYP19A1/Aromatase</i>	ACTACAACCGGTATATGGAGAA	TCGAGAGCTGTAATGATTGTGC
<i>CYP21A2</i>	CATCCAAATTGTGGACGTGATTC	CCACGATGTGATCCCTCTTCTC
<i>HPRT1</i>	ACCAGTCAACAGGGGACATAA	CTTCGTGGGGTCCTTTTCACC
<i>HSD3B1</i>	CACATGGCCCGCTCCATAC	GTGCCCGGTTTTTCAGATTTC
<i>HSD3B2</i>	CTTGTGCGTTAAGACCCACAT	GGGTTGACTGTAGAGAACTTTCC
<i>LHB*</i>	GCTACTGCCCCACCATGATG	ATGGACTCGAAGCGCACATC
		AGAGCCACAGGGAAGGAGAC
		AGCTGAGAGCCACAGGGAAG
<i>TBP</i>	CACGAACCACGGCACTGATT	TTTTCTTGCTGCCAGTCTGGAC

Primer sequences used for *NR0B1/DAX1* sequence.

	Forward	Reverse
<i>NR0B1 Exon1-1</i>	TGAGACAGGGAAAGGGTAAT	CCGGGTCATCGCCGCACGAA
<i>NR0B1 Exon1-2</i>	TGGTGGATCAGTGTGGGGC	CCGGGATCAGAGCCGCACGAA
<i>NR0B1 Exon1-3</i>	AAGCAAACGTACGCGGCAC	CCTCTGCGCGAAGTAGGAGC
<i>NR0B1 Exon1-4</i>	TAGCTCAAAGCAAACGCACGTG	GACGCCAGCAGTTGCGCAC
<i>NR0B1 Exon1-5</i>	GCCTCAGCGGGCCTGTTGAAG	CCCAGTGTCTTTGTGAGCTGGAA
<i>NR0B1 Exon2-1</i>	GCTAGCAAAGGACTCTGTGGT	TGTGTGGCCACATGACTTTA

Primer sequences used for mutagenesis of *NR0B1/DAX1*.

Gene	Forward	Reverse
<i>NR0B1 mutagenesis primer</i>	CACATGCTTGAGCTGGCCAGGACCGCT	CAGGGACGCCAGCAGTTGCGCACC

*For *LHB*, one forward primer was combined with different reverse primers